New drug for the treatment of rheumatoid arthritis shows promising success

In a clinical phase-3-study, an international research cooperation has achieved significant success with the drug Baricitinib for the treatment of rheumatoid arthritis. The test persons exhibited significantly less symptoms of the disorder.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Publication date: Available online 18 January 2019Source: Journal of Advanced ResearchAuthor(s): Mohamed N. Saad, Mai S. Mabrouk, Ayman M. Eldeib, Olfat G. ShakerAbstractThe human genome, which includes thousands of genes, represents a big data challenge. Rheumatoid arthritis (RA) is a complex autoimmune disease with a genetic basis. Many single-nucleotide polymorphism (SNP) association methods partition a genome into haplotype blocks. The aim of this genome wide association study (GWAS) was to select the most appropriate haplotype block partitioning method for the North American Rheumatoid Arthritis Consortium (NARAC) dat...
Source: Journal of Advanced Research - Category: Research Source Type: research
Publication date: Available online 17 January 2019Source: Joint Bone SpineAuthor(s): Xavier Romand, Chloé Bernardy, Minh Vu Chuong Nguyen, Anaïs Courtier, Candice Trocme, Margot Clapasson, Marie-Hélène Paclet, Bertrand Toussaint, Philippe Gaudin, Athan BailletABSTRACTCalprotectin is a calcium binding protein produced by neutrophils and monocytes locally at the site of inflammation in order to trigger the innate immunity receptors. This unique characteristic makes it a good proxy for evaluation of local inflammation in chronic inflammatory rheumatic diseases. Complete data suggest, in inflammatory ...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Authors: Fernandes JG, Borrego A, Jensen JR, Cabrera WHK, Correa MA, Starobinas N, Ribeiro OG, Ibañez OM, De Franco M Abstract Pristane-induced arthritis (PIA) in mice is an experimental model that resembles human rheumatoid arthritis, a chronic autoimmune disease that affects joints and is characterized by synovial inflammation and articular cartilage and bone destruction. AIRmax and AIRmin mouse lines differ in their susceptibility to PIA, and linkage analysis in this model mapped arthritis severity QTLs in chromosomes 5 and 8. miRNAs are a class of small RNA molecules that have been extensively studied in...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Authors: Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, Paul D Abstract AIMS: To estimate real world healthcare costs and resource utilization of rheumatoid arthritis (RA) patients associated with targeted disease modifying anti-rheumatic drugs (tDMARD) switching in general and switching to abatacept specifically. MATERIALS AND METHODS: RA patients initiating a tDMARD were identified in IMS PharMetrics Plus health insurance claims data (2010-2016), and outcomes measured included monthly healthcare costs per patient (all-cause, RA-related) and resource utilization (inpatient stays, outpatient visi...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
ConclusionThis molecular mechanism of the investigation confirmed the clinical efficacy of Kashayams in preventing the progression of RA and gave an intuition of the scientific validation of Kashayams, an Ayurvedic classical medicine.
Source: Journal of Ayurveda and Integrative Medicine - Category: Complementary Medicine Source Type: research
In this study, the efficacy of clarithromycin in protecting against pulmonary fibrosis was investigated in the rat model for methotrexate-induced pulmonary fibrosis. Material and methods: A total of 30 female rats were divided into three groups. Group I was administered intraperitoneal and intragastric saline; group II was administered oral 3 mg/kg methotrexate; and group III was administered oral 3 mg/kg methotrexate + intraperitoneal 200 mg/kg clarithromycin for 28 days. Histopathological analyses of the lung tissues were performed under light microscopy. Results: Normal histopathological changes were observed in t...
Source: Polish Journal of Cardio-Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Kardiochir Torakochirurgia Pol Source Type: research
RHEUMATOID arthritis symptoms include joint pain, inflammation, and restricted movement. But the condition, which affects about 400,000 people in the UK, could also cause this feeling in your eyes - are you at risk?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
ConclusionsIn Mexican patients from the tofacitinib global RA program, tofacitinib efficacy was demonstrated up to Month 12 in Phase 3 studies and Month 36 in the LTE study, with a safety profile consistent with tofacitinib global population.ResumenObjetivosTofacitinib es un inhibidor de la cinasa Janus para el tratamiento de la artritis reumatoide (AR). Se evaluaron la eficacia y la seguridad de tofacitinib en pacientes mexicanos a partir de los estudios fase 3 y de extensión a largo plazo (ELP) de AR.Mèc)todosDatos de pacientes mexicanos con AR y respuesta inadecuada a fármacos antirreumáticos...
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
CHICAGO—With an ever-strengthening foundation beneath the pathophysiology and prediction of rheumatoid arthritis (RA), the field may soon focus more intently on prevention, an expert said at the 2018 ACR/ARHP Annual Meeting. The session also covered the latest in remission targets and therapy de-escalation. RA Prevention Kevin Deane, MD, PhD, associate professor of medicine and principal... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Meeting Reports Rheumatoid Arthritis 2018 ACR/ARHP Annual Meeting prevention Remission treatment de-escalation Source Type: research
Objective. Currently no guidelines are established for pharmacogenomic testing involving folate metabolic genes in long-term disease-modifying antirheumatic drugs (DMARD) therapies. We carefully investigated how common genetic variations in methylenetetrahydrofolate reductase ( MTHFR ) influence cellular metabolic kinetics in response to methotrexate (MTX). Designs. Two distinct cell models: HepG2 with stabilized MTHFR  inhibition using shRNA delivered by a Lentiviral vector; and Epstein-Barr virus transformed human lymphoblasts expressing MTHFR polymorphic allele 677C and 677T were used.  Disease activity a...
Source: Clinical Science - Category: Biomedical Science Authors: Tags: PublishAheadOfPrint Source Type: research
More News: Arthritis | Rheumatoid Arthritis | Rheumatology | Science | Study